Form 4: DexCom Director Sells Shares Under 10b5-1 Plan

DexCom Director Mark G. Foletta sold a total of 6,530 shares of common stock through his family trust, executing trades under a pre-arranged 10b5-1 plan.

Summary

• Mark G. Foletta, a Director at DexCom Inc. (DXCM), reported the sale of 6,530 shares of common stock.
• The sales occurred on June 15, 2026, and were conducted through The Foletta Family Trust.
• These transactions were executed under a Rule 10b5-1(c) trading plan adopted by the Trust on March 13, 2026, which allows for the orderly disposition of shares.
• A total of 3,801 shares were sold at a weighted average price of $74.0991.
• An additional 199 shares were sold at a weighted average price of $74.8187.
• The filing also notes 6,331 unvested restricted stock units granted on May 28, 2026, which vest one year after the grant date or at DexCom's 2027 Annual Meeting of Stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While insider selling can be a negative signal, the use of a 10b5-1 plan indicates a structured and compliant disposition of shares, mitigating concerns about opportunistic trading.

Positives

• The sales were conducted under a Rule 10b5-1(c) plan, indicating a pre-determined and structured approach to stock disposition, which can mitigate concerns about insider trading.
• The company continues to grant restricted stock units, suggesting a commitment to long-term employee incentives and retention.

Negatives

• A Director has sold a significant number of shares, which could be perceived negatively by the market, although the 10b5-1 plan provides context.
• The total number of shares sold by the Director is 6,530.

Risks

• While the sales are under a 10b5-1 plan, significant insider selling can sometimes signal a lack of confidence in future stock performance, although this is not explicitly stated.
• The value of the unvested restricted stock units is subject to vesting conditions and potential fluctuations in DexCom's stock price.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's financial performance. It primarily reports on past transactions.

Management Comments

• The Foletta Family Trust DTD 1/30/2015 (the "Trust") adopted a 10b5-1 Plan.
• This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust.
• The shares set forth above were sold pursuant to the 10b5-1 Plan.
• The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

Industry Context

StockSavvy.ai notes that Form 4 filings, particularly those involving 10b5-1 plans, are common for directors and officers. The execution of these plans is a standard practice for managing personal stock portfolios while adhering to insider trading regulations. The specific details of the sales, including the volume and pricing, are crucial for investors to assess any potential signals from insider activity.

Stakeholder Impact

• Shareholders: May interpret the director's stock sales, even under a 10b5-1 plan, as a potential signal, though the plan itself is designed to reduce negative implications.
• Management: The use of 10b5-1 plans by directors is a standard governance practice.
• Employees: The granting of restricted stock units indicates continued investment in employee compensation and retention.

Next Steps

• The Foletta Family Trust may continue to dispose of shares under the 10b5-1 plan.
• Unvested restricted stock units granted on May 28, 2026, are scheduled to vest on the earlier of the one-year anniversary of the grant date or DexCom, Inc.'s 2027 Annual Meeting of Stockholders.

Key Dates

Keywords

DexCom, DXCM, Form 4, Insider Trading, 10b5-1 Plan, Stock Sale, Director, Beneficial Ownership, Restricted Stock Units, Foletta Family Trust